Guideline for the Use of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Autoimmune Neuromuscular Disorders

Česká verzia

Authors: J. Bednařík& ^{1 *}; S. Voháňka ^2*; E. Ehler ^3*; Z. Ambler ^4**; J. Piťha ^5**; J. Vencovský ^6**; J. Litzman ^7***; Z. Kořístek ^8***; M. Suchý ^9****; M. Pátá ^9****; P. Kožený ^9****; &garant; Autor ^*; Konzultant ^**; Oponent ^***; Člen Vývojového Týmu ^****
Authors place of work: Člen výboru Neuromuskulární sekce (NMS) České neurologické společnosti (ČNS) ČLS JEP a místopředseda ČNS ČLS JEP ¹; Předseda NMS ČNS ČLS JEP ²; Člen výboru NMS ČNS ČLS JEP a ČNS ČLS JEP ³; Člen výboru NMS ČNS ČLS JEP a ČNS ČLS JEP ⁴; Vedoucí lékař Centra pro léčbu myasthenia gravis Neurologické kliniky 1. LF UK a VFN v Praze ⁵; Předseda České revmatologické společnosti ČLS JEP ⁶; Vědecký sekretář České společnosti alergologie a klinické imunologie ČLS JEP ⁷; Vedoucí separačního střediska, Interní hematoonkologická klinika LF MU a FN Brno ⁸; Národní referenční centrum, Praha ⁹
Published in the journal: Cesk Slov Neurol N 2010; 73/106(5): 579-589
Category: Standard Treatment

Zdroje

1. Pritchard J. What’s new in Guillain-Barré syndrome? Pract Neurol 2006; 6; 208–217.

2. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72(18): 1548–1554.

3. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13(4): 326–332.

4. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Periph Nerv Syst 2005; 10(3): 220–228.

5. Hadden RD, Nobile-Orazio E, Sommer C, Hahn A, Illa I, Morra E et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006; 13(8): 802–808.

6. Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008, 15(9): 893–908.

7. Donofrio PD, Berger A, Brannagan TH jr, Bromberg MB, Howard JF, Latov N et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions. Report of the AANEM ad hoc committee. Muscle Nerve 2009; 40(5): 890–900.

8. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991; 41(5): 617–618.

9. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; 1: CD001797.

10. Hughes RA, Swan AV, van Doorn PA. Corticosteoids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006; 1: CD001446.

11. Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; 2: CD003906.

12. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2002; 2: CD001798.

13. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2009; 1: CD001327.

14. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2009; 2: CD004429.

15. Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol 2004; 11(9): 577–581.

16. Podmínky vzniku center pro diagnostiku a léčbu nervosvalových onemocnění v ČR [online]. Dostupné z URL: http://www.neuromuskularni-sekce.cz/.

17. Bohan A, Peter JB. Polymyositis and dermatomyositis I. N Engl J Med 1975; 292(7): 344–347.

18. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22(4): 668–674.

19. Targoff IN, Miller FW, Medsger, TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9(6): 527–536.

20. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362(9388): 971–982.

21. Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130(9): 2245–2257.

22. Kleyweg RP, van der Meché FG, Schmitz PI: Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 1991; 14(10): 997–1002.

23. Hughes R, Bensa S, Willison H, van der Bergh P, Comi G, Illa I et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50(2): 195–201.

24. Scottish Intercollegiate Guidelines Network (SIGN) (2002): Management of patients with stroke. A national clinical guideline [online]. Dostupné z: www.sign.ac.uk.

25. Amato AA, Dumitru D. Acquired Neuropathies. In: Dumitru D, Amato AA, Swarth MJ (eds). Electrodiagnostic Medicine. 2nd ed. Philadelphia: Hanley & Belfus 2002: 937–1041.

26. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366(9497): 1653–1666.